Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2025 | Bridging real-world data and clinical trials in leptomeningeal disease

Evangelia Razis • 1 May 2025
ESMO Breast 2025
Breast Cancer

Evangelia Razis, MD, PhD, Hygeia Hospital, Marousi, Greece, discusses the evolving strategies to translate insights from real-world registries into effective clinical trial design for leptomeningeal disease (LMD) in breast cancer. She highlights recent initiatives, including the development of standardized criteria such as the ESMO Guidance for Reporting Oncology real-World evidence (GROW) guidelines, and efforts to clarify research priorities to ensure meaningful, resource-efficient outcomes. These frameworks aim to enhance the reproducibility and impact of future trials in this underserved patient population. This interview took place at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Munich, Germany.

All content is owned by Magdalen Medical Publishing (MMP) and protected under international copyright laws. All rights reserved.

More from Evangelia Razis

Advancing research in leptomeningeal disease from registries to clinical trials
2:18
Advancing research in leptomeningeal disease from registries to clinical trials
Evangelia Razis • 1 May 2025
Emerging therapeutic and diagnostic strategies in leptomeningeal disease
1:12
Emerging therapeutic and diagnostic strategies in leptomeningeal disease
Evangelia Razis • 1 May 2025

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals